Actively Recruiting
Phase II Study of BL-B01D1 with PD-1 Antibody for Unresectable or Recurrent Metastatic Triple-negative Breast Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-07-23
52
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of BL-B01D1 and a PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer. This phase II study aims to explore the efficacy and safety of this treatment approach in patients who have not previously received systemic therapy for their advanced disease. Participants receive BL-B01D1 by intravenous infusion on days 1 and 8 of a 3-week cycle, along with PD-1 monoclonal antibody administered by intravenous infusion every 3 weeks. Those showing clinical benefit may continue treatment for additional cycles until disease progression, intolerable side effects, or other reasons for stopping treatment occur. During the study, participants will undergo regular evaluations including tumor assessments to measure response, safety monitoring, and laboratory tests. The primary outcomes include objective response rate and recommended phase II dose, with secondary outcomes covering progression-free survival, disease control rate, duration of response, and treatment-emergent adverse events. The study duration for outcome measurement is up to approximately 24 months.
CONDITIONS
Brief Title
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here